Cardiac toxicity from systemic cancer therapy: A comprehensive review

Progress in Cardiovascular Diseases

Volumn 53, Issue 2, 2010, Pages 94-104

  Curigliano, Giuseppe ^a   Mayer, Erica L ^b   Burstein, Harold J ^b   Winer, Eric P ^b   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AROMATASE INHIBITOR; ARSENIC TRIOXIDE; BEVACIZUMAB; CARBOPLATIN; CARDIOVASCULAR AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IDARUBICIN; IFOSFAMIDE; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ADJUVANT THERAPY; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; NONHODGKIN LYMPHOMA; OVARY CANCER; PERICARDIAL EFFUSION; PERICARDITIS; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT RESPONSE; CARDIOLOGY; CHEMICALLY INDUCED; COOPERATION; HEART DISEASES; INTERDISCIPLINARY COMMUNICATION; NEOPLASMS; ONCOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; RISK ASSESSMENT; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CARDIOLOGY; COOPERATIVE BEHAVIOR; HEART DISEASES; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT CARE TEAM; RISK ASSESSMENT; RISK FACTORS;

EID: 77955876140     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.05.006     Document Type: Review

References (108)

1. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
2. Bird B.R., Swain S.M. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008, 14:14-24.
3. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
4. Gianni L., Baselga J., Eiermann W., et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009, 27:2474-2481.
5. Grenier M.A., Lipshultz S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25:72-85.
6. O'Brien M.E., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
7. Kalyanaraman B. Iron signaling and oxidant damage. Cardiovasc Toxicol 2007, 7:92-94.
8. Wallace K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 2007, 7:101-107.
9. Lebrecht D, Walker U.A. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7:108-113.
10. Swift L., McHowart J., Sarvazyan N. Anthracycline induced phospholipase A2 inhibition. Cardiovascular Toxicology 2007, 7:86-91.
11. Kang Y.J. Antioxidant defense against anthracycline cardiotoxicity by metallothionein. Cardiovasc Toxicol 2007, 7:95-100.
12. Braverman A.C., Antin J.H., Plappert M.T., et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991, 9:1215-1223.
13. Goldberg M.A., Antin J.H., Guinan E.C., et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986, 68:1114-1118.
14. Gottdiener J.S., Appelbaum F.R., Ferrans V.J., et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981, 141:758-763.
15. Quezado Z.M., Wilson W.H., Cunnion R.E., et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993, 118:31-36.
16. Gharib M.I., Burnett A.K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002, 4:235-242.
17. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313.
18. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
19. Del Mastro L., Perrone F., Repetto L., et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005, 16:253-258.
20. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC->T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC->TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. San Antonio 2009 Annual Breast Cancer meeting. Cancer Res 2009, 69:62.
21. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
22. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
23. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
24. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
25. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
26. de Azambuja E., Bedard P.L., Suter T., et al. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?. Target Oncol 2009, 4:77-88.
27. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
28. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
29. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
30. McArthur H.L., Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007, 357:94-95.
31. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008, 26:1231-1238.
32. Sawyer D.B., Zuppinger C., Miller T.A., et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002, 105:1551-1554.
33. Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378:394-398.
34. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
35. Chien K.R. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006, 354:789-790.
36. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
37. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107-4115.
38. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
39. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
40. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
41. Sledge G.W. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002, 29:104-110.
42. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
43. Miles D., Chan A., Dirix L.Y., et al. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2010, 28:3239-3247.
44. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2009, 27:15s. (suppl;1005).
45. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
46. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
47. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
48. Miller K.D., O'Neill A., Perez E.A., et al. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Clin Oncol 2008, 26. (suppl; abstr 520).
49. McArthur H., Rugo H., Nulsen B., et al. Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer. Cancer Res 2009, 69:4104.
50. Allegra C.J., Yothers G., O'Connell M.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009, 27:3385-3390.
51. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
52. Perez E.A., Koehler M., Byrne J., et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008, 83:679-686.
53. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
54. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
55. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
56. Telli M.L., Witteles R.M., Fisher G.A., et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19:1613-1618.
57. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
58. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
59. Overmoyer B., Fu P., Hoppel C., et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res 2007, 13:5862-5868.
60. Meyer C.C., Calis K.A., Burke L.B., et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997, 17:729-736.
61. Van Cutsem E., Hoff P.M., Blum J.L., et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002, 13:484-485.
62. Cardinale D., Colombo A., Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol 2006, 22:251-253.
63. de Forni M., Malet-Martino M.C., Jaillais P., et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992, 10:1795-1801.
64. Kosmas C., Kallistratos M.S., Kopterides P., et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008, 134:75-82.
65. Rezkalla S., Kloner R.A., Ensley J., et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989, 7:509-514.
66. Robben N.C., Pippas A.W., Moore J.O. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993, 71:493-509.
67. Labianca R., Beretta G., Clerici M., et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982, 68:505-510.
68. Jensen S.A., Sorensen J.B. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006, 58:487-493.
69. Singer M. Cardiotoxicity and capecitabine: a case report. Clin J Oncol Nurs 2003, 7:72-75.
70. Saif M.W., Tomita M., Ledbetter L., et al. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol 2008, 6:41-48.
71. Rowinsky E.K., McGuire W.P., Guarnieri T., et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991, 9:1704-1712.
72. Arbuck S.G., Strauss H., Rowinsky E., et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993, 117-130.
73. McArthur H., Rugo H., Nulsen B., et al. Troponins do not predict cardiotoxicity in a pilot study of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P). Cancer Res 2009, 69:3087.
74. Cuppone F., Bria E., Verma S., et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008, 112:260-267.
75. Maitland M.L., Bakris G.L., Black H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010.
76. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
77. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
78. Baselga J., Roche H., et al. SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 2009, 69:45. Grupo Espanol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Solidos.
79. Laurie S.A., Gauthier I., Arnold A., et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008, 26:1871-1878.
80. Azpiroz F., Bouin M., Camilleri M., et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007, 19:62-88.
81. Azad N.S., Posadas E.M., Kwitkowski V.E., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26:3709-3714.
82. Mayer E.L., Hamel S., Savoie J., et al. AZD2171 for refractory breast cancer: a phase 2 trial. breast. Cancer Res Treat 2007, 106:S274.
83. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010, 28:49-55.
84. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
85. NIH National Cancer Institute common terminology criteria for adverse events (CTCAE) and Common Toxicity Criteria (CTC). NIH 2009, Last accessed July 23, 2010. http://ctep.cancer.gov/reporting/ctc.html.
86. Wu S., Chen J.J., Kudelka A., et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9:117-123.
87. Izzedine H., Ederhy S., Goldwasser F., et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20:807-815.
88. Langenberg M.H., van Herpen C.M., De Bono J., et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol 2009, 27:6152-6159.
89. Ozcan C., Wong S.J., Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-982. [discussion -2].
90. Allen J.A., Adlakha A., Bergethon P.R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006, 63:1475-1478.
91. Rixe O., Billemont B., Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007, 18:1117.
92. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
93. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-1795.
94. Verheul H.M., Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485.
95. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006, 24:1363-1369.
96. Mourad J.J., des Guetz G., Debbabi H., et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008, 19:927-934.
97. Steeghs N., Gelderblom H., Roodt J.O., et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008, 14:3470-3476.
98. Hood J.D., Meininger C.J., Ziche M., et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998, 274:H1054-H1058.
99. Olsson A.K., Dimberg A., Kreuger J., et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
100. Vyzantiadis T., Karagiannis A., Douma S., et al. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin Exp Hypertens 2006, 28:603-609.
101. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006, 6:521-534.
102. Barbey J.T., Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001, 135:842-843.
103. Ohnishi K., Yoshida H., Shigeno K., et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000, 133:881-885.
104. Huan S.Y., Yang C.H., Chen Y.C. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Leuk Lymphoma 2000, 38:283-293.
105. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
106. Galetta F., Franzoni F., Cervetti G., et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005, 59:541-544.
107. Nousiainen T., Vanninen E., Rantala A., et al. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 1999, 245:359-364.
108. Liu X.K., Katchman A., Ebert S.N., et al. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 1998, 287:877-883.